MARVF yields 71428.57% · PFE yields 6.13%● Live data
📍 MARVF pulled ahead of the other in Year 1
Combined, MARVF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MARVF + PFE for your $10,000?
Marvel Discovery Corp. engages in the acquisition, exploration, and development of mineral properties in Canada. The company has an option to acquire a 100% interest in the Duhamel Property consists of nine mineral claims covering an area of approximately 500 hectares located northwest of the city of the Saguenay, Quebec; the Wicheeda North project comprises 18 claims that covers 4,423.8 hectares situated Northeast of Prince George, British Columbia; and the Blackfly property that includes five claims consisting of 64 unpatented mining claims located in Atikokan, Ontario. It also has an option to acquire a 100% interest in Slip Gold property consists of six claims with 264 claim units situated in Newfoundland; the Victoria/Long Lake comprises five claims with 53 claim units located in Newfoundland; the East Bull property, which includes 16 mineral claims situated in the Deagle, Gaiashk, and Gerow mining district, Ontario; and the Sandy Pond and Baie Verte Line property comprising 335 mineral claims located in the Province of Newfoundland and Labrador, as well as holds interest in Gander South project comprises 14 mineral claims situated in Newfoundland. In addition, Marvel Discovery Corp. has an option to acquire a 100% interest in the Highway North property consists of five contiguous claims totaling 2,573 hectares located in the Athabasca region of Saskatchewan. The company was formerly known as International Montoro Resources Inc. and changed its name to Marvel Discovery Corp. in February 2021. Marvel Discovery Corp. was incorporated in 1987 and is headquartered in Vancouver, Canada.
Full MARVF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.